| Aug 1 |
BridgeBio Pharma: Q2 Earnings Snapshot
|
| Aug 1 |
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
|
| Jul 23 |
BridgeBio Pharma appoints Thomas Trimarchi COO
|
| Jul 23 |
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
|
| Jun 27 |
BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
|
| Jun 18 |
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
|
| Jun 6 |
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
|
| Jun 5 |
The 3 Best Biotech Stocks to Buy in June 2024
|
| Jun 4 |
BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug
|
| Jun 4 |
BridgeBio releases new phase 2 results for infigratinib for achondroplasia
|
